CN105358142A - 靶向睑板腺的营养补充剂 - Google Patents

靶向睑板腺的营养补充剂 Download PDF

Info

Publication number
CN105358142A
CN105358142A CN201480027112.4A CN201480027112A CN105358142A CN 105358142 A CN105358142 A CN 105358142A CN 201480027112 A CN201480027112 A CN 201480027112A CN 105358142 A CN105358142 A CN 105358142A
Authority
CN
China
Prior art keywords
eyelid
oil
handicapped
tarsal glands
quality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480027112.4A
Other languages
English (en)
Chinese (zh)
Inventor
S.G.史密斯
M.B.格罗斯
O.E.桑德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC
Original Assignee
PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49947054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105358142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC filed Critical PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC
Publication of CN105358142A publication Critical patent/CN105358142A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480027112.4A 2013-03-12 2014-02-05 靶向睑板腺的营养补充剂 Pending CN105358142A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/815,599 US9381183B2 (en) 2012-07-18 2013-03-12 Methods for improving the quality of the meibum composition of meibomian glands
US13/815599 2013-03-12
PCT/US2014/014937 WO2014158356A1 (en) 2013-03-12 2014-02-05 Nutritional supplement targeting meibomian glands

Publications (1)

Publication Number Publication Date
CN105358142A true CN105358142A (zh) 2016-02-24

Family

ID=49947054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027112.4A Pending CN105358142A (zh) 2013-03-12 2014-02-05 靶向睑板腺的营养补充剂

Country Status (10)

Country Link
US (1) US9381183B2 (ja)
EP (1) EP2968243B1 (ja)
JP (2) JP6538022B2 (ja)
KR (1) KR101904850B1 (ja)
CN (1) CN105358142A (ja)
CA (1) CA2904737C (ja)
CL (1) CL2015002713A1 (ja)
ES (1) ES2743614T3 (ja)
PE (1) PE20160123A1 (ja)
WO (1) WO2014158356A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US9115078B2 (en) * 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
RU2589703C2 (ru) 2011-09-12 2016-07-10 Тасос ГЕОРГИУ Применение омега жирных кислот для лечения заболевания
US20150125394A1 (en) * 2012-06-19 2015-05-07 Santen Pharmaceutical Co., Ltd. Method for changing condition of eyelid of hairless animal
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
JP6497812B2 (ja) * 2013-06-28 2019-04-10 学校法人慶應義塾 マイボーム腺機能不全の処置剤
CA2951162C (en) * 2014-06-04 2019-04-23 Tersus Pharmaceuticals, LLC Methods of treating chronic dry eye disease using c16:1n7-palmitoleate and derivatives thereof
WO2018005685A1 (en) * 2016-06-29 2018-01-04 Physicians Recommended Nutriceuticals, Llc Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
WO2021148845A1 (en) * 2020-01-23 2021-07-29 Visufarma S.P.A. Ophthalmic composition for the treatment of dry eye disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US20110111055A1 (en) * 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye
US20120258168A1 (en) * 2011-04-07 2012-10-11 Amerisciences, Lp Methods and compositions to promote ocular health

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
AU775189B2 (en) 1999-11-09 2004-07-22 Alcon Inc. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US20060127505A1 (en) 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US6649195B1 (en) 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US7041840B2 (en) 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
CN101043884A (zh) * 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
DE202004015931U1 (de) 2004-10-13 2005-01-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
BRPI0620210A2 (pt) 2005-12-20 2011-11-01 Alcon Res Ltd composição e processos para a inibição da progressão da degeneração macular e para promover visão saudável
WO2008143642A2 (en) 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
EP1932520A1 (en) 2006-12-15 2008-06-18 Novartis AG Nutritional supplement composition for treatment of ocular diseases
EP1932521A1 (en) 2006-12-15 2008-06-18 Novartis AG Nutritional supplement composition for treatment of ocular diseases
US20090226547A1 (en) 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
JP2012505162A (ja) 2008-10-09 2012-03-01 ワラタ ファーマシューティカルズ， インコーポレイテッド 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
KR20120115380A (ko) * 2010-01-11 2012-10-17 지티엑스, 인코포레이티드 마이봄선 기능 장애의 치료 방법
EP2641597A4 (en) * 2010-11-19 2014-04-30 Nippon Suisan Kaisha Ltd THERAPEUTIC OR PROPHYLACTIC AGENT FOR CORNEAL EPITHELIUM DISORDERS AND / OR CONNECTIVE EPITHELIUM DISORDERS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US20110111055A1 (en) * 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye
US20120258168A1 (en) * 2011-04-07 2012-10-11 Amerisciences, Lp Methods and compositions to promote ocular health

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用

Also Published As

Publication number Publication date
EP2968243A4 (en) 2016-09-14
JP2016512245A (ja) 2016-04-25
KR101904850B1 (ko) 2018-10-08
EP2968243B1 (en) 2019-06-19
US9381183B2 (en) 2016-07-05
CA2904737C (en) 2019-11-26
PE20160123A1 (es) 2016-03-03
JP6538022B2 (ja) 2019-07-03
EP2968243A1 (en) 2016-01-20
CA2904737A1 (en) 2014-10-02
US20140024625A1 (en) 2014-01-23
CL2015002713A1 (es) 2016-09-30
ES2743614T3 (es) 2020-02-20
KR20150126405A (ko) 2015-11-11
WO2014158356A1 (en) 2014-10-02
JP2019058194A (ja) 2019-04-18

Similar Documents

Publication Publication Date Title
CN105358142A (zh) 靶向睑板腺的营养补充剂
US9115078B2 (en) Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
Bhargava et al. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers
Downie et al. Oral omega-3 supplementation lowers intraocular pressure in normotensive adults
KR102665229B1 (ko) 안구 건조 질환 및 마이봄선염의 치료를 위한 조성물
US20160067204A1 (en) Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
Downie et al. An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial
Hesselink et al. Resolvins and aliamides: lipid autacoids in ophthalmology–what promise do they hold?
US7029712B1 (en) Treatment for dry eye syndrome
KR101262076B1 (ko) 각막 질환의 치료를 위한 식이 보조제 또는 의약품의제조를 위한 ｌ-카르니틴 또는 알카노일 ｌ-카르니틴, 지질수용성 벤조퀴논 및 오메가-3-다불포화 지방산을 포함하는병용제의 용도
Gilbard The diagnosis and management of dry eyes
Silva et al. Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits
US10709680B2 (en) Methods for treating dry eye
US11648227B2 (en) Omega-3 fatty acid supplementation for use in treating dry eye
Jain et al. Role of Omega-3 fatty acids in meibomian gland dysfunction
CN105214092B (zh) 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途
US20160310456A1 (en) Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
WO2018005685A1 (en) Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure
Hsu et al. Effects of Supplementation with Lutein Plus Docosahexaenoic Acid Oral Complex on Eye Dryness, Visual Function, and Memory Function in Healthy Subjects: A Single‐Arm Clinical Trial
Franke et al. Neuromodulation for Treatment of Dry Eye
Raoof-Daneshvar et al. Nonmedical treatments for dry eye
Maciver Dry eye disease and blepharitis review
Johnston Dry eyes: eye care
BECKMAN Toward Dropless Inflammation Control in Cataract Surgery
Lang Maqui berry extract and Omega-3–the natural ingredient combination to keep your eyes moist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160224

RJ01 Rejection of invention patent application after publication